Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

H. Sehn, Laurie; F. Herrera, Alex; R. Flowers, Christopher; Kamdar, Manali; McMillan, Andrew; Hertzberg, Mark; Assouline, Sarit; Min Kim, Tae; Seog Kim, Won; Özcan, Muhıt; Hirata, Jamie; Penuel, Elicia; N. Paulson, Joseph; Cheng, Ji; Ku, Grace; J. Matasar, Matthew

doi:10.1200/jco.19.00172

Public

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Published in Journal of Clinical Oncology • Nov 6, 2019

Authors:

Laurie H. Sehn

Alex F. Herrera

Christopher R. Flowers

Abstract

PURPOSE Patients with transplantation-ineligible relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) fare poorly, with limited treatment options. The antibody-drug conjugate polatuzumab vedotin targets CD79b, a B-cell receptor component. METHODS Safety and efficacy of polatuzumab vedotin...

Subject

Medicine

Internal medicine

Bendamustine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!